CVE-2023-33365
HIGHCVSS 7.5/10EPSS 0.72%
Last modified
CVE-2023-33365 is a high-severity vulnerability rated 7.5/10 on the CVSS scale. A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.. EPSS estimates a 0.72% chance of exploitation in the next 30 days.
Description
A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.
Metrics
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
Weakness Enumeration
Affected Software
| Vendor | Product | Versions |
|---|---|---|
| Supremainc | Biostar 2 | < 2.9.1 |
References
- https://claroty.com/team82/disclosure-dashboard/cve-2023-33365Third Party Advisory
- https://kb.supremainc.com/knowledge/doku.php?id=en:release_note_291Release Notes, Vendor Advisory
- https://claroty.com/team82/disclosure-dashboard/cve-2023-33365Third Party Advisory
- https://kb.supremainc.com/knowledge/doku.php?id=en:release_note_291Release Notes, Vendor Advisory
Timeline
- Published
- Last Modified
- Status
- Modified
Frequently Asked Questions
What is CVE-2023-33365?
A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to fetch arbitrary files from the server's web server.
How severe is CVE-2023-33365?
CVE-2023-33365 has a CVSS score of 7.5/10 (HIGH severity). The EPSS model estimates a 0.72% probability of exploitation in the next 30 days.
How do I fix CVE-2023-33365?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.
Are you affected by CVE-2023-33365?
Run a free Strix scan to check your systems for this vulnerability.
Scan your code nowSource: NVD / NIST